Jungel and colleagues found upon oral application of a highly selective MMP-13 inhibitor that arthritis was significantly decreased in the severe combined immunodeficiency and collagen-induced arthritis model, whereas no significant effects were seen in the antibody-induced arthritis model [16]. Here, MMP13 is linked to arthritic joint disease.